Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration

Acta Obstetricia et Gynecologica Scandinavica

Volumn 75, Issue 2, 1996, Pages 162-165

  Taga, Michiyoshi ^a   Minaguchi, Hiroshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Bone metabolic parameter; Bone mineral density; Endometriosis; GnRH agonist; Nafarelin; Osteoporosis

Indexed keywords

GONADORELIN AGONIST; NAFARELIN;

ABSORPTIOMETRY; ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ENDOMETRIOSIS; HUMAN; INTRANASAL DRUG ADMINISTRATION; LUMBAR VERTEBRA; METABOLIC PARAMETERS; OSTEOPOROSIS; PRIORITY JOURNAL; VERTEBRA;

EID: 0029981598     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.3109/00016349609033310     Document Type: Article

References (12)

1. Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, and Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med 1988; 318: 485-9.
2. Nencioni T, Penotti M, Barbieri-Carones M, Ortolani S, Trevisan C, Polvani F. Gonadotropin releasing hormone agonist therapy and its effect on bone mass. Gynecol Endocrinol 1991; 5: 49-56.
3. 3. J Clin Endocrinol Metab 1990; 70: 1055-61.
4. Matta WH, Shaw RW, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypoestrogenism with the GnRH analogue buserelin in premenopausal women. Clinical Endocrinol 1988; 29: 45-51.
5. Dodin S, Lemay A, Matheux R, Dumont M, Turcot-Lemay L. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 1991; 77: 410-15.
6. Taga M, Minaguchi H, Terakawa N, Tanizawa O, Sugimoto O, Hoshiai H et al.Treatment of endometriosis with nafarelin In: The treatment of endometriosis Recent developments in fertility and sterility series Vol. 4, pp. 61-65, The Parthenon Publishing Group UK and USA, 1990.
7. Comite F, Jensen P. Lewis A, Hutchinson K, Polan ML, DeCherney A. GnRH analog therapy in endometriosis: impact on bone mass. Presented at 34th Annual Meeting of the Society for Gynecologic Investigations, Atlanta, March 18-21, 1987; p.76 (Abstr.)
8. Cann CE, Henzel MR, Burry K, Andreko J, Hanson F, Adamson D et al. Reversible bone loss is produced by the GnRH agonist nafarelin. In Cohn DY Martin TJ, Meunier PJ (eds.). Calcium regulation and bone metabolism: basic and clinical aspects. (Amsterdam, Elsevier) 1987; p. 123.
9. Johnansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67: 701-6.
10. Waibel-Treber S. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma. Human Rep 1989; 4: 384-8.
11. Dawood MY, Lewis V, Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fert Steril 1989; 52: 21-6.
12. Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990; 70: 920-4.